Clinical AI capabilities and diagnostic innovation for New Zealand & Oceania.
The Translyx Limited pipeline spans governed clinical AI workflow capabilities — under evaluation and development — and diagnostic innovation across AMR, sepsis, point-of-care testing, oncology, endocrine, cardiac, and precision medicine.
Clinical AI workflow capabilities
Governed workflow capabilities in the Translyx pipeline
Privacy-preserving, reviewer-gated clinical AI workflow concepts being evaluated and developed under the Translyx platform — designed with human oversight, visible limitations, and clinical governance from the outset.
Pipeline capabilities are under evaluation or in development. They are not publicly launched products and are not currently available to customers. No regulatory endorsement is implied.
Pipeline capability
AI Wrapper
Secure LLM gateway for privacy-preserving AI use
Learn morePipeline capability
Cloud Shield
Field-level protection for cloud platforms and data workflows
Learn morePipeline capability
Scribe
Privacy-protected clinical documentation and structured notes
Learn morePipeline capability
Trace
Reviewer-gated evidence and synthetic control workflows
Learn morePipeline capability
ClinicalTriage
Clinical pathway and referral grading support for authorised healthcare teams
Learn moreDiagnostic innovation
Diagnostic technology opportunities for New Zealand healthcare
Globally validated diagnostic and clinical technology areas Translyx is working to bring to New Zealand — across antimicrobial resistance, sepsis, point-of-care testing, oncology, endocrine, cardiac, and precision medicine.
Authorised partner solution
Aiforia Digital Pathology AI
Translyx is an authorised non-exclusive business partner of Aiforia Technologies Plc in New Zealand, representing Aiforia Clinical Suites and Aiforia Create Platform. Aiforia strengthens the oncology biomarkers, digital pathology, and precision medicine areas of this pipeline.
Antibacterial Resistance
Antibacterial resistance remains an urgent public health concern even in New Zealand. While overall resistance rates here are lower than in some neighbouring regions, resistant strains are increasingly detected.
Learn more
Sepsis
Sepsis is a leading cause of serious illness and death, and it places a heavy burden on healthcare systems in New Zealand and internationally. In Aotearoa, sepsis is responsible for tens of thousands of infections annually.
Learn more
Oncology Biomarkers
Cancer remains a significant health challenge in New Zealand, with more than 30,000 people expected to be diagnosed each year in 2025. Accurate and timely biomarker testing is a cornerstone of modern oncology.
Learn more
Cardiac Biomarkers
Cardiovascular disease remains one of the leading causes of death and health burden in New Zealand. Cardiac biomarkers play a central role in diagnosing acute coronary syndromes and stratifying risk.
Learn more
Endocrine Biomarkers
Endocrine disorders such as diabetes, thyroid disease, and metabolic syndromes are highly prevalent in New Zealand. Accurate measurement of endocrine biomarkers is essential for diagnosing disease and guiding clinical interventions.
Learn more
Point of Care Testing
Point of care testing (POCT) is increasingly recognised as a vital part of modern healthcare delivery. POCT helps reduce turnaround times by providing diagnostic results near the patient.
Learn moreDiscuss the Translyx pipeline for your organisation.
Contact Translyx to discuss how pipeline capabilities and diagnostic innovation fit your healthcare or research priorities.